Dar Bioscience to Participate in Two Upcoming Investor Conferences – Yahoo Finance

SAN DIEGO, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Dar Bioscience, Inc. (DARE), a leader in womens health innovation, today announced that Sabrina Johnson, its President and Chief Executive Officer, will present at two upcoming investor conferences:

A live webcast of Ms. Johnsons presentation at the Dawson James conference will be available on the Investor Relations section of Dars website at http://ir.darebioscience.com. Following the live broadcast, a replay will be available through November 12, 2019.

AboutDar Bioscience

Dar Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for womens health. The companys mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.

Dars product portfolio includes potential first-in-category candidates in clinical development: Ovaprene, a hormone-free, monthly contraceptive intravaginal ring; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause. To learn more about Dars full portfolio of womens health product candidates, and mission to deliver differentiated therapies for women, please visit http://www.darebioscience.com.

Dar may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Dar uses these channels to communicate with its investors and the public about the company and other company-related matters. The information Dar posts on its investor relations website may be deemed to be material information. Dar encourages investors, the media, and others interested in the company to review the information Dar posts on its investor relations website: http://www.darebioscience.com.

Contacts:Investors on behalf of Dar Bioscience, Inc.:Lee RothBurns McClellanlroth@burnsmc.com212.213.0006

OR

Media on behalf of Dar Bioscience, Inc.:Jake RobisonCanale Communicationsjake@canalecomm.com619.849.5383

Source: Dar Bioscience

Continued here:
Dar Bioscience to Participate in Two Upcoming Investor Conferences - Yahoo Finance